• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Study Purpose

This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria.

  • - Participants must have.
  • - Metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC) (without known targetable EGFR, ALK, ROS1, or BRAF mutations) who either.
  • - a) have not yet received frontline therapy for metastatic disease and without prior exposure to anti PD-1/PD-L1 or.
  • - b) are relapsed/refractory with progression on anti PD-1/PD therapy.
  • - Relapsed/refractory metastatic cutaneous melanoma (regardless of mutation status) with progression on a PD-1 inhibitor.
  • - Metastatic head and neck squamous cell carcinoma (HNSCC) who have not yet received frontline therapy for metastatic disease and without prior exposure to a PD-1/PD-L1 inhibitor.
  • - Cohorts 1-4 only: Melanoma participants must be currently on PD-1 checkpoint inhibitor (CPI) therapy (e.g. nivolumab or pembrolizumab) or had their last dose of PD-1 CPI containing therapy as the last previous line of therapy within 90 days prior to enrollment; PD-1 CPI therapy must be the immediate prior line of treatment.
  • - Cohorts 1-4 only: Participants must have progressed on treatment with an anti-PD-1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other CPIs or other therapies.
PD-1 treatment progression is defined by meeting all of the following criteria.
  • - Have received at least 2 doses of an approved PD-1 inhibitor.
  • - Have demonstrated disease progression (PD) after a PD-1 inhibitor as defined by RECIST v1.1.
  • - Progressive disease has been documented within 90 days from the last dose of PD-1 inhibitor.
  • - Participants with melanoma will need iRECIST confirmation of progression with a second assessment at least four weeks after the initial date of progressive disease.
  • - NSCLC participants on PD-1 inhibitor containing therapy for less than 90 days will need iRECIST confirmation of progression at least 4 weeks after the initial date of progressive disease.
  • - Tumor tissue sample obtained within 3 months prior to enrollment is required, and no systemic anticancer therapy given after the sample was obtained.
  • - An Eastern Cooperative Oncology Group (ECOG) Performance Status score of equal or less than 1.
Exclusion Criteria.
  • - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • - Prior immunosuppressive chemotherapy, any immunotherapy other than a PD-1 inhibitor within 4 weeks of first study drug dose.
  • - History of another malignancy within 3 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04609566
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Seagen, a wholly owned subsidiary of Pfizer
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Pfizer CT.gov Call Center
Principal Investigator Affiliation Pfizer
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Combination Therapy

brentuximab vedotin + pembrolizumab

Interventions

Drug: - brentuximab vedotin

1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks

Drug: - pembrolizumab

200 mg given intravenously every 3 weeks

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Arizona Oncology Associates, PC - HOPE, Tucson 5318313, Arizona 5551752

Status

Address

Arizona Oncology Associates, PC - HOPE

Tucson 5318313, Arizona 5551752, 85704

Arizona Oncology Associates, PC - HOPE, Tucson 5318313, Arizona 5551752

Status

Address

Arizona Oncology Associates, PC - HOPE

Tucson 5318313, Arizona 5551752, 85711

Arizona Oncology Associates, PC - HOPE, Tucson 5318313, Arizona 5551752

Status

Address

Arizona Oncology Associates, PC - HOPE

Tucson 5318313, Arizona 5551752, 85745

Highlands Oncology Group, PA, Fayetteville 4110486, Arkansas 4099753

Status

Address

Highlands Oncology Group, PA

Fayetteville 4110486, Arkansas 4099753, 72703

Highlands Oncology Group, PA, Rogers 4128894, Arkansas 4099753

Status

Address

Highlands Oncology Group, PA

Rogers 4128894, Arkansas 4099753, 72758

Highlands Oncology Group, PA, Springdale 4132093, Arkansas 4099753

Status

Address

Highlands Oncology Group, PA

Springdale 4132093, Arkansas 4099753, 72762

Encinitas 5346646, California 5332921

Status

Address

California Cancer Associates for Research and Excellence, Inc (cCARE)

Encinitas 5346646, California 5332921, 92024

Fresno 5350937, California 5332921

Status

Address

California Cancer Associates for Research and Excellence, Inc. cCARE

Fresno 5350937, California 5332921, 93720

Los Angeles 5368361, California 5332921

Status

Address

The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate

Los Angeles 5368361, California 5332921, 90025

Los Angeles 5368361, California 5332921

Status

Address

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI)

Los Angeles 5368361, California 5332921, 90048

San Marcos 5392368, California 5332921

Status

Address

California Cancer Associates for Research and Excellence Inc (cCARE)

San Marcos 5392368, California 5332921, 92069

Santa Monica 5393212, California 5332921

Status

Address

The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-Up Only)

Santa Monica 5393212, California 5332921, 90404

Rocky Mountain Cancer Centers, LLP, Aurora 5412347, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Aurora 5412347, Colorado 5417618, 80012

Aurora 5412347, Colorado 5417618

Status

Address

Clinical and Translational Research Center (CTRC)

Aurora 5412347, Colorado 5417618, 80045

Aurora 5412347, Colorado 5417618

Status

Address

University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)

Aurora 5412347, Colorado 5417618, 80045

Aurora 5412347, Colorado 5417618

Status

Address

University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)

Aurora 5412347, Colorado 5417618, 80045

Aurora 5412347, Colorado 5417618

Status

Address

University of Colorado Hospital-Anschutz Cancer Pavilion (ACP)

Aurora 5412347, Colorado 5417618, 80045

Rocky Mountain Cancer Centers, LLP, Boulder 5574991, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Boulder 5574991, Colorado 5417618, 80303

Rocky Mountain Cancer Centers, LLP, Colorado Springs 5417598, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Colorado Springs 5417598, Colorado 5417618, 80907

Rocky Mountain Cancer Centers, LLP, Denver 5419384, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Denver 5419384, Colorado 5417618, 80218

Rocky Mountain Cancer Centers, LLP, Denver 5419384, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Denver 5419384, Colorado 5417618, 80220

Rocky Mountain Cancer Centers, LLP, Lakewood 5427946, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Lakewood 5427946, Colorado 5417618, 80228

Rocky Mountain Cancer Centers, LLP, Littleton 5429032, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Littleton 5429032, Colorado 5417618, 80120

Rocky Mountain Cancer Centers, LLP, Lone Tree 5429208, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Lone Tree 5429208, Colorado 5417618, 80124

Rocky Mountain Cancer Centers, LLP, Longmont 5579276, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Longmont 5579276, Colorado 5417618, 80504

Rocky Mountain Cancer Centers, LLP, Pueblo 5435464, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Pueblo 5435464, Colorado 5417618, 81003

Rocky Mountain Cancer Centers, LLP, Thornton 5441492, Colorado 5417618

Status

Address

Rocky Mountain Cancer Centers, LLP

Thornton 5441492, Colorado 5417618, 80260

Northwestern Medical Group, Chicago 4887398, Illinois 4896861

Status

Address

Northwestern Medical Group

Chicago 4887398, Illinois 4896861, 60611

Northwestern Memorial Hospital, Chicago 4887398, Illinois 4896861

Status

Address

Northwestern Memorial Hospital

Chicago 4887398, Illinois 4896861, 60611

University of Kansas Medical Center, Kansas City 4273837, Kansas 4273857

Status

Address

University of Kansas Medical Center

Kansas City 4273837, Kansas 4273857, 66160

Westwood 4281639, Kansas 4273857

Status

Address

The University of Kansas Cancer Center, Investigational Drug Services

Westwood 4281639, Kansas 4273857, 66205

The University of Kansas Cancer Center, Westwood 4281639, Kansas 4273857

Status

Address

The University of Kansas Cancer Center

Westwood 4281639, Kansas 4273857, 66205

Norton Cancer Institute Downtown, Louisville 4299276, Kentucky 6254925

Status

Address

Norton Cancer Institute Downtown

Louisville 4299276, Kentucky 6254925, 40202

Norton Hospital, Louisville 4299276, Kentucky 6254925

Status

Address

Norton Hospital

Louisville 4299276, Kentucky 6254925, 40202

Norton Audubon Hospital, Louisville 4299276, Kentucky 6254925

Status

Address

Norton Audubon Hospital

Louisville 4299276, Kentucky 6254925, 40217

Louisville 4299276, Kentucky 6254925

Status

Address

Norton Cancer Institute, Audubon Hospital Campus

Louisville 4299276, Kentucky 6254925, 40217

Norton Brownsboro Hospital, Louisville 4299276, Kentucky 6254925

Status

Address

Norton Brownsboro Hospital

Louisville 4299276, Kentucky 6254925, 40241

Louisville 4299276, Kentucky 6254925

Status

Address

Norton Cancer Institute, Brownsboro Hospital Campus

Louisville 4299276, Kentucky 6254925, 40241

Minnesota Oncology Hematology PA, Burnsville 5019767, Minnesota 5037779

Status

Address

Minnesota Oncology Hematology PA

Burnsville 5019767, Minnesota 5037779, 55337

Minnesota Oncology Hematology PA, Coon Rapids 5022025, Minnesota 5037779

Status

Address

Minnesota Oncology Hematology PA

Coon Rapids 5022025, Minnesota 5037779, 55433

Minnesota Oncology Hematology PA, Edina 5025264, Minnesota 5037779

Status

Address

Minnesota Oncology Hematology PA

Edina 5025264, Minnesota 5037779, 55435

Minnesota Oncology Hematology PA, Fridley 5027482, Minnesota 5037779

Status

Address

Minnesota Oncology Hematology PA

Fridley 5027482, Minnesota 5037779, 55432

Minnesota Oncology Hematology PA, Maple Grove 5036493, Minnesota 5037779

Status

Address

Minnesota Oncology Hematology PA

Maple Grove 5036493, Minnesota 5037779, 55369

Minnesota Oncology Hematology PA, Maplewood 5036588, Minnesota 5037779

Status

Address

Minnesota Oncology Hematology PA

Maplewood 5036588, Minnesota 5037779, 55109

Minnesota Oncology Hematology PA, Minneapolis 5037649, Minnesota 5037779

Status

Address

Minnesota Oncology Hematology PA

Minneapolis 5037649, Minnesota 5037779, 55404

Minnesota Oncology Hematology PA, Plymouth 5041926, Minnesota 5037779

Status

Address

Minnesota Oncology Hematology PA

Plymouth 5041926, Minnesota 5037779, 55441

Minnesota Oncology Hematology PA, Saint Paul 5045360, Minnesota 5037779

Status

Address

Minnesota Oncology Hematology PA

Saint Paul 5045360, Minnesota 5037779, 55102

Minnesota Oncology Hematology PA, Woodbury 5053358, Minnesota 5037779

Status

Address

Minnesota Oncology Hematology PA

Woodbury 5053358, Minnesota 5037779, 55125

Bellevue 5063805, Nebraska 5073708

Status

Address

Nebraska Medicine - Bellevue Medical Center

Bellevue 5063805, Nebraska 5073708, 68123

Nebraska Medicine, Omaha 5074472, Nebraska 5073708

Status

Address

Nebraska Medicine

Omaha 5074472, Nebraska 5073708, 68105

Nebraska Medicine - Village Pointe, Omaha 5074472, Nebraska 5073708

Status

Address

Nebraska Medicine - Village Pointe

Omaha 5074472, Nebraska 5073708, 68118

University Of Nebraska Medical Center, Omaha 5074472, Nebraska 5073708

Status

Address

University Of Nebraska Medical Center

Omaha 5074472, Nebraska 5073708, 68198

New York Oncology Hematology, P.C., Albany 5106834, New York 5128638

Status

Address

New York Oncology Hematology, P.C.

Albany 5106834, New York 5128638, 12206

New York Oncology Hematology, P.C., Albany 5106834, New York 5128638

Status

Address

New York Oncology Hematology, P.C.

Albany 5106834, New York 5128638, 12208

New York Oncology Hematology, P.C., Clifton Park 5112961, New York 5128638

Status

Address

New York Oncology Hematology, P.C.

Clifton Park 5112961, New York 5128638, 12065

Cincinnati 4508722, Ohio 5165418

Status

Address

Oncology_Hematology Care Clinical Trials,LLC

Cincinnati 4508722, Ohio 5165418, 45211

Cincinnati 4508722, Ohio 5165418

Status

Address

Oncology_Hematology Care Clinical Trials,LLC

Cincinnati 4508722, Ohio 5165418, 45236

Cincinnati 4508722, Ohio 5165418

Status

Address

Oncology_Hematology Care Clinical Trials,LLC

Cincinnati 4508722, Ohio 5165418, 45242

Cincinnati 4508722, Ohio 5165418

Status

Address

Oncology_Hematology Care Clinical Trials,LLC

Cincinnati 4508722, Ohio 5165418, 45245

Fairfield 4511283, Ohio 5165418

Status

Address

Oncology_Hematology Care Clinical Trials,LLC

Fairfield 4511283, Ohio 5165418, 45014

Toledo Clinic Cancer Center, Toledo 5174035, Ohio 5165418

Status

Address

Toledo Clinic Cancer Center

Toledo 5174035, Ohio 5165418, 43623

Oncology Associates of Oregon, P.C., Eugene 5725846, Oregon 5744337

Status

Address

Oncology Associates of Oregon, P.C.

Eugene 5725846, Oregon 5744337, 97401

Texas Oncology - Austin, Austin 4671654, Texas 4736286

Status

Address

Texas Oncology - Austin

Austin 4671654, Texas 4736286, 78705

Texas Oncology - Austin, Austin 4671654, Texas 4736286

Status

Address

Texas Oncology - Austin

Austin 4671654, Texas 4736286, 78731

Texas Oncology - Austin, Austin 4671654, Texas 4736286

Status

Address

Texas Oncology - Austin

Austin 4671654, Texas 4736286, 78745

Texas Oncology-DFW, Dallas 4684888, Texas 4736286

Status

Address

Texas Oncology-DFW

Dallas 4684888, Texas 4736286, 75246

Fort Worth 4691930, Texas 4736286

Status

Address

Texas Oncology - Fort Worth Cancer Center

Fort Worth 4691930, Texas 4736286, 76104

Texas Oncology-DFW, Fort Worth 4691930, Texas 4736286

Status

Address

Texas Oncology-DFW

Fort Worth 4691930, Texas 4736286, 76104

Oncology Consultants, PA, Houston 4699066, Texas 4736286

Status

Address

Oncology Consultants, PA

Houston 4699066, Texas 4736286, 77024

Irving 4700168, Texas 4736286

Status

Address

US Oncology Investigational Product Center (IPC)

Irving 4700168, Texas 4736286, 75063

Irving 4700168, Texas 4736286

Status

Address

US Oncology Investigational Products Center (IPC)

Irving 4700168, Texas 4736286, 75063

Blacksburg 4747845, Virginia 6254928

Status

Address

Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Blacksburg 4747845, Virginia 6254928, 24060

Virginia Oncology Associates, Chesapeake 4752186, Virginia 6254928

Status

Address

Virginia Oncology Associates

Chesapeake 4752186, Virginia 6254928, 23320

Fairfax 4758023, Virginia 6254928

Status

Address

Inova Schar Cancer Institue Infusion Pharmacy

Fairfax 4758023, Virginia 6254928, 22031

Inova Schar Cancer Institute, Fairfax 4758023, Virginia 6254928

Status

Address

Inova Schar Cancer Institute

Fairfax 4758023, Virginia 6254928, 22031

Virginia Oncology Associates, Hampton 4762894, Virginia 6254928

Status

Address

Virginia Oncology Associates

Hampton 4762894, Virginia 6254928, 23666

Low Moor 4770856, Virginia 6254928

Status

Address

Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Low Moor 4770856, Virginia 6254928, 24457

Virginia Oncology Associates, Newport News 4776024, Virginia 6254928

Status

Address

Virginia Oncology Associates

Newport News 4776024, Virginia 6254928, 23606

Virginia Oncology Associates, Norfolk 4776222, Virginia 6254928

Status

Address

Virginia Oncology Associates

Norfolk 4776222, Virginia 6254928, 23502

Richmond 4781708, Virginia 6254928

Status

Address

Virginia Commonwealth University Massey Cancer Center

Richmond 4781708, Virginia 6254928, 23219

VCU Health Stony Point, Richmond 4781708, Virginia 6254928

Status

Address

VCU Health Stony Point

Richmond 4781708, Virginia 6254928, 23235

Richmond 4781708, Virginia 6254928

Status

Address

Massey Cancer Center Clinical & Translational Research Lab

Richmond 4781708, Virginia 6254928, 23298

Richmond 4781708, Virginia 6254928

Status

Address

Tissue and Data Acquisition and Analysis Core (TDAAC)

Richmond 4781708, Virginia 6254928, 23298

Richmond 4781708, Virginia 6254928

Status

Address

VCU Health- Adult Outpatient Pavilion (AOP) Investigational Drug Services

Richmond 4781708, Virginia 6254928, 23298

Virginia Commonwealth University, Richmond 4781708, Virginia 6254928

Status

Address

Virginia Commonwealth University

Richmond 4781708, Virginia 6254928, 23298

Roanoke 4782167, Virginia 6254928

Status

Address

Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Roanoke 4782167, Virginia 6254928, 24014

Salem 4784112, Virginia 6254928

Status

Address

Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Salem 4784112, Virginia 6254928, 24153

VCU Health Tappahannock Hospital, Tappahannock 4788822, Virginia 6254928

Status

Address

VCU Health Tappahannock Hospital

Tappahannock 4788822, Virginia 6254928, 22560

Virginia Oncology Associates, Virginia Beach 4791259, Virginia 6254928

Status

Address

Virginia Oncology Associates

Virginia Beach 4791259, Virginia 6254928, 23456

Virginia Oncology Associates, Williamsburg 4793846, Virginia 6254928

Status

Address

Virginia Oncology Associates

Williamsburg 4793846, Virginia 6254928, 23188

Wytheville 4794837, Virginia 6254928

Status

Address

Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Wytheville 4794837, Virginia 6254928, 24382

Fred Hutchinson Cancer Care Center, Seattle 5809844, Washington 5815135

Status

Address

Fred Hutchinson Cancer Care Center

Seattle 5809844, Washington 5815135, 98109

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact